Andros
竟天生物科技股份有限公司
Andros is a Taiwan Emerging Stock Board biotechnology company; its most advanced asset is APC101 (Phase 2 / Phase 3; not yet recruiting, PHN - Post-Herpetic Neuritis), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| APC101 | — | Phase 2 / Phase 3; not yet recruiting | PHN - Post-Herpetic Neuritis | Australia, United States | 2026-05-20 | Trial registry |
| APC201 | — | — | — | — | 2026-03-04 | Company disclosure |
Key events
No verified events in the past twelve months.
Related Drugnews articles
No related articles in this language.